Menu Search
Equities

Eli Lilly and Co

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LILY34:SAO

Eli Lilly and Co

Actions
  • Price (BRL)176.41
  • Today's Change-0.58 / -0.33%
  • Shares traded35.77k
  • 1 Year change-2.37%
  • Beta--
Data delayed at least 15 minutes, as of Mar 03 2026 19:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LLY:NYQ since
announced		Transaction
value
Orna Therapeutics IncAnnounced09 Feb 202609 Feb 2026Announced-4.89%2.40bn
Ventyx Biosciences IncAnnounced07 Jan 202607 Jan 2026Announced-5.41%1.01bn
Adverum Biotechnologies IncDeal completed24 Oct 202524 Oct 2025Deal completed22.58%274.32m
Verve Therapeutics IncDeal completed17 Jun 202517 Jun 2025Deal completed24.62%1.25bn
SiteOne Therapeutics IncDeal completed27 May 202527 May 2025Deal completed41.02%1.00bn
Data delayed at least 15 minutes, as of Mar 03 2026 19:16 GMT.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Caixa DTVM SAas of 31 Oct 2025303.03k0.00%
Safra Asset CTVM SA (Investment Management)as of 31 Oct 202546.60k0.00%
XP Advisory Gest�o Recursos Ltda.as of 31 Oct 20255.31k0.00%
Credit Suisse Hedging-Griffo Wealth Management SAas of 31 Oct 20254.79k0.00%
XP Allocation Asset Management Ltda.as of 31 Oct 20254.07k0.00%
BTG Pactual Gest�o E Consultoria De Investimentos Ltda.as of 31 Oct 20252.29k0.00%
Banco BTG Pactual SA (Investment Management)as of 30 Sep 2025110.000.00%
More ▼
Data from 31 Oct 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.